Patients who switch to natalizumab have better outcomes than those who continue on the same platform therapy after a relapse

Authors
Category Primary study
JournalEuropean Journal of Neurology
Year 2014
This article has no abstract
Epistemonikos ID: 5d356114057c894fbdf89cfe606d4fe31c91bdc2
First added on: Feb 06, 2025